Journal of Applied Physiology Watch the video to see how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Appl Physiol 72: 1212-1217, 1992;
8750-7587/92 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Minkes, R. K.
Right arrow Articles by Kadowitz, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Minkes, R. K.
Right arrow Articles by Kadowitz, P. J.

Journal of Applied Physiology, Vol 72, Issue 3 1212-1217, Copyright © 1992 by American Physiological Society

ARTICLES

Differential effects of PACAP and VIP on the pulmonary and hindquarters vascular beds of the cat

R. K. Minkes, T. J. McMahon, J. S. Hood, W. A. Murphy, D. H. Coy, D. B. McNamara and P. J. Kadowitz
Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana 70112.

Responses to pituitary adenylate cyclase-activating polypeptide (PACAP), a novel peptide derived from ovine hypothalamus with 68% sequence homology with vasoactive intestinal polypeptide (VIP), were investigated in the pulmonary and hindquarters vascular beds of the anesthetized cat under conditions of controlled blood flow. Injection of the peptide into the perfused lung lobe under elevated tone conditions produced dose-dependent decreases in lobar arterial pressure that were accompanied by biphasic changes in systemic arterial pressure characterized by an initial decrease followed by a secondary increase in pressure. When compared with other vasodilator agents in the pulmonary vascular bed, the relative order of potency was isoproterenol greater than PACAP greater than acetylcholine greater than calcitonin gene-related peptide greater than VIP. In the hindquarters vascular bed, intra-arterial injections of PACAP produced biphasic changes in hindquarters perfusion pressure characterized by initial decreases followed by secondary increases, which were accompanied by biphasic changes in systemic arterial pressure. In terms of relative vasodilator activity in the hindlimb, the order of relative potency was isoproterenol greater than acetylcholine greater than calcitonin gene-related peptide greater than VIP greater than PACAP. PACAP was the only agent that caused a secondary vasoconstrictor response in the hindlimb and produced biphasic changes in systemic arterial pressure. D-Phe2-VIP, a VIP receptor antagonist, blocked the hindquarters vasodilation in response to VIP but had no effect on responses to PACAP. The present investigation shows that PACAP produces pulmonary vasodilation, as well as dilation, and vasoconstriction in the systemic (hindlimb) vascular bed.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
M. Hautmann, U. G. Friis, M. Desch, V. Todorov, H. Castrop, F. Segerer, C. Otto, G. Schutz, and F. Schweda
Pituitary Adenylate Cyclase-Activating Polypeptide Stimulates Renin Secretion via Activation of PAC1 Receptors
J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1150 - 1156.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C. Otto, L. Hein, M. Brede, R. Jahns, S. Engelhardt, H.-J. Grone, and G. Schutz
Pulmonary Hypertension and Right Heart Failure in Pituitary Adenylate Cyclase-Activating Polypeptide Type I Receptor-Deficient Mice
Circulation, November 16, 2004; 110(20): 3245 - 3251.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
N. M. Sherwood, S. L. Krueckl, and J. E. McRory
The Origin and Function of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)/Glucagon Superfamily
Endocr. Rev., December 1, 2000; 21(6): 619 - 670.
[Abstract] [Full Text]

Home page
 Pharmacol. Rev.Home page
D. Vaudry, B. J. Gonzalez, M. Basille, L. Yon, A. Fournier, and H. Vaudry
Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: From Structure to Functions
Pharmacol. Rev., June 1, 2000; 52(2): 269 - 324.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
E. J. Whalen, A. K. Johnson, and S. J. Lewis
Tachyphylaxis to PACAP-27 after inhibition of NO synthesis: a loss of adenylate cyclase activation
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 1999; 277(5): R1453 - R1461.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
E. J. Whalen, M. D. Travis, A. K. Johnson, and S. J. Lewis
Rapid tachyphylaxis to hemodynamic effects of PACAP-27 after inhibition of nitric oxide synthesis
Am J Physiol Heart Circ Physiol, June 1, 1999; 276(6): H2117 - H2126.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
L. Bruch, S. Rubel, A. Kästner, K. Gellert, M. Gollasch, and C. Witt
Pituitary adenylate cyclase activating peptides relax human pulmonary arteries by opening of KATP and KCa channels
Thorax, July 1, 1998; 53(7): 586 - 587.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online